US2018044367A1PendingUtilityA1

Nucleoside phosphoramidates

68
Assignee: GILEAD PHARMASSET LLCPriority: May 20, 2009Filed: Mar 28, 2017Published: Feb 15, 2018
Est. expiryMay 20, 2029(~2.9 yrs left)· nominal 20-yr term from priority
A61K 45/00A61K 31/716C07F 9/65586A61P 31/12C07H 19/10A61K 31/7072A61P 31/00A61P 1/16C07F 9/242Y02P20/55A61P 31/14C07F 9/24A61K 31/67A61P 3/12C07H 1/00A61K 31/675C07H 17/02A61P 31/16A61K 31/664Y02A50/30
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

Claims

exact text as granted — not AI-modified
1 .- 81 . (canceled) 
     
     
         82 . A compound of formula: 
       
         
           
           
               
               
           
         
       
       wherein Z is —C(O)(CH 2 ) 2 C(O)CH 3,  —Si(CH 3 ) 2   t Bu or —Si(i—Pr) 2 -O—Si(i—Pr) 2 -OH.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.